Abstract
Objective: To investigate whether APOE ε4 genotype—an established risk factor for dementia—is associated with earlier age at diagnosis in addition to increased risk overall and in secondary analysis by race and sex.Methods: We followed up 13,782 dementia-free individuals (n = 10,137 White, n = 3,645 Black, baseline age 60–66 years) in the Atherosclerosis Risk in Communities study for up to 30 years. Dementia was operationalized using standardized algorithms incorporating longitudinal cognitive change, proxy report, and hospital or death certificate dementia codes. We used a mixture of generalized gamma distributions to simultaneously estimate time to dementia, time to dementia-free death, and the proportion of individuals with dementia, by APOE ε4 status (≥1 vs. no alleles).Results: Median age of dementia onset among APOE ε4 carriers was 81.7 (Blacks) and 83.3 years (Whites) compared with 82.6 (Blacks) and 85.7 years (Whites) in non-APOE ε4 carriers (p > 0.05 Blacks; p < 0.01 Whites). Age of dementia diagnosis did not differ by sex in ε4 carriers, but among non-carriers, average age was earlier in males than females regardless of race. APOE ε4 carriers had on average a higher proportion of diagnoses; results did not differ by race or sex.Conclusions: APOE ε4 carrier status is associated with earlier age of dementia diagnosis with differences across race and sex. These findings clarify the causal role of APOE in dementia etiology, which could help better identify at-risk subgroups and may help facilitate better research trial recruitment and design.
Highlights
Carriers of the apolipoprotein (APOE) ε4 allele contribute to 7% of incident global dementia cases and have double the risk of developing mild cognitive impairment (MCI) and dementia [1, 2] than have non-carriers
We jointly modeled both age of diagnosis and risk of dementia diagnosis or death, accounting for the competing risk of death [13] over 30 years in the Atherosclerosis Risk in Communities (ARIC) study
White APOE ε4 carriers had a similar age of dementia diagnosis of 83.3 and 83.4 years for males and females, respectively, yet demonstrated differing ages for non-ε4 carriers
Summary
Carriers of the apolipoprotein (APOE) ε4 allele contribute to 7% of incident global dementia cases and have double the risk of developing mild cognitive impairment (MCI) and dementia [1, 2] than have non-carriers. Risk of dementia is greater in Blacks compared with Whites, the relative effect of APOE ε4 may be greater. APOE and Dementia in Whites compared with Blacks, potentially because a larger component of the risk seen in Blacks is due to other health factors such as vascular disease [7,8,9]. Most prior studies of APOE ε4 and dementia only estimate risk of dementia. An additional limitation of prior studies is that most have failed to account for death, which can bias risk estimates for dementia [12, 13]. One of the few studies to do so found over two times greater risk for Alzheimer’s disease among White individuals who are heterozygous ε4 carriers as compared with non-carriers [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
